Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

NCT00721279 · clinicaltrials.gov ↗

COMPLETED

Status

549

Enrollment

INDUSTRY

Sponsor class

Conditions

Restless Legs Syndrome

Interventions

DRUG: Sifrol® (pramipexole dihydrochloride)

Sponsor

Boehringer Ingelheim